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Adenovirus vectors offer a platform technology for vaccine development. The value of the platform 
has been proven during the COVID-19 pandemic. Although good stability at 2–8 °C is an advantage of 
the platform, non-cold-chain distribution would have substantial advantages, in particular in low-
income countries. We have previously reported a novel, potentially less expensive thermostabilisation 
approach using a combination of simple sugars and glass micro-fibrous matrix, achieving excellent 
recovery of adenovirus-vectored vaccines after storage at temperatures as high as 45 °C. This matrix 
is, however, prone to fragmentation and so not suitable for clinical translation. Here, we report an 
investigation of alternative fibrous matrices which might be suitable for clinical use. A number of 
commercially-available matrices permitted good protein recovery, quality of sugar glass and moisture 
content of the dried product but did not achieve the thermostabilisation performance of the original 
glass fibre matrix. We therefore further investigated physical and chemical characteristics of the glass 
fibre matrix and its components, finding that the polyvinyl alcohol present in the glass fibre matrix 
assists vaccine stability. This finding enabled us to identify a potentially biocompatible matrix with 
encouraging performance. We discuss remaining challenges for transfer of the technology into clinical 
use, including reliability of process performance.
Vaccine immunogens are composed of complex biological macromolecules. Good immunogenicity requires 
stability of these molecules throughout the lifespan of a product, from production and formulation, through 
transportation and storage to delivery to the recipient. Extrinsic factors such as light, pH, agitation and oxidants 
combine with temperature fluctuations to challenge product stability. Therefore, most vaccines need to be con-
tinuously stored in refrigerators or freezers. Maintaining the cold chain and associated logistics in vaccination 
campaigns can contribute up to 45% of the total cost of  vaccination1. On the other hand, damage as a result of 
cold chain breakages costs several million dollars  annually2. These issues affect not only low income countries, 
where the cold chain is regarded as being least reliable, but also developed  countries3–5. The vaccines responsi-
ble for eradication of smallpox and rinderpest (the only two diseases eradicated by immunisation) were both 
thermostable, a factor believed to contribute to their  success6. Development of technologies to enhance vaccine 
thermostability has therefore been a major focus of research  effort7.
Viral vectored vaccines, in particular adenoviruses, are versatile platforms for development of novel vaccines 
against emerging  pathogens8,9,  malaria10,11, HIV-AIDS12,13,  tuberculosis14 and  influenza15,16. The platform has 
proven its value in response to the COVID-19 pandemic, providing the basis for vaccines developed by Janssen, 
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the Gamaleya Institute and Cansino, in addition to the Oxford/Astrazeneca vaccine (Vaxzevria) which we con-
tributed to developing. The rapid platform manufacturing process is attractive for emergency  response17,18. 
Successful thermostabilisation of adenovirus vectored vaccines could thus be valuable for products targeting a 
wide range of diseases.
There have been a number of efforts to enhance stability of adenovirus-based vaccines in liquid formula-
tions, achieving stability for several months at 2–8 °C or a number of weeks at 15–30 °C19–21. Other groups have 
reported improvement in stability by drying vaccines using  lyophilisation22,23, spray  drying24–26, and nano-patch 
 technology27, in some cases demonstrating short-term stability (weeks) at temperatures up to 37 °C20.
We have previously reported that drying a formulation of adenovirus in glass forming sugars upon a fibrous 
matrix such as paper or a wetlaid nonwoven fabric permitted full recovery of viable and immunogenic virus, 
even after 6 months at 45 °C28–30. We are not aware of any other reports of adenovirus stabilisation at such tem-
peratures. We refer to this method as sugar-matrix thermostabilisation (SMT). As well as thermostabilisation 
performance, advantages of SMT include a relatively short process duration (in some cases as little as 18 h) and 
avoidance of the stress of extreme in-process temperature exposure involved in lyophilisation and spray drying.
Our previous published SMT work used a glass fibre matrix and a polypropylene matrix; we reported that the 
glass fibre matrix achieved better stability than the polypropylene  matrix28. Glass fibre matrix is however prone 
to shedding of non-biocompatible fibres, and so not suitable for clinical translation.
Here, we present results from an effort to characterise the factors contributing to the performance of glass 
fibre matrix and to test alternative matrices more suitable for clinical use. An overview of our strategy is presented 
in schematic form in Fig. 1.
Results
Glass fibre matrix achieves good stability but is not suitable for clinical development. In our 
previously published work, we had used low vaccine doses (1.1 ×  1010 viral particles per matrix, as compared to a 
typical human dose of 5 ×  1010 viral particles), applied to the glass fibre matrix ‘Standard 14’ (S14, GE Healthcare, 
Fig. 2A)28. We speculate that the fibrous matrix provides a high surface area, favouring relatively rapid drying 
of the product despite the gentle conditions used (18–24 h at 20–23 °C and atmospheric pressure). The process 
results in films of vitreous ‘sugar glass’ embedded in the matrix (Fig. 2B). As previously reported, this ‘base-case’ 
process achieves a sugar glass transition temperature  (Tg) after drying of 47–55 °C, with moisture content 3–5% 
of total solute dry  weight28.
We have now dried full human doses (5 ×  1010 virus particles, approximately 5 ×  108 infectious units [IU]) of 
a simian adenovirus vectored rabies vaccine (ChAdOx2 RabG) upon 1  cm2 of the matrix, with < 0.1  log10-fold 
loss in-process (i.e. during desiccation) and approximately 0.3  log10-fold loss after thermochallenge at 30 °C for 
a month (Fig. 2C)30. For explanation of the  log10-fold loss metric, please see “Methods”.
Despite the good thermostabilisation performance of the glass fibre matrix, we were concerned that the 
brittleness of glass fibre would result in shedding of fibres during the process of vaccine reconstitution. Indeed, 
macroscopic damage to the matrix was sometimes apparent at the point of reconstitution. We therefore sought 
Starng point & problem: SMT using glass fibre matrix ‘S14’ can stabilise adenovirus 
for storage at 30-45 °C, but the glass fibre is brile and unsuitable for clinical use.
Inially-tested alternave matrices did not stabilise adenovirus adequately
Mulple differences between the inial matrices were idenfied. 
These could not be clearly linked to thermostabilising
performance, so these matrices were not evaluated further.
Further examinaon of S14 idenfied the presence of polyvinyl alcohol (PVA). When 
added to other glass fibre matrices, PVA was found to improve adenovirus stability. 
Commercially available PVA matrices were found to achieve good adenovirus stability.
Insight from this study: PVA can contribute to adenovirus stability and may offer a 
biocompable opon for SMT processes. Greater consistency of SMT performance 
would, however, sll be required for clinical translaon.  
Figure 1.  Scheme of investigation. The research strategy used in the current work is presented in terms of 
research questions and answers, leading from a starting point and problem statement to a conclusion and 
identification of a key remaining challenge.
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to quantify subvisible particles (0.1–100 μm) in the reconstituted vaccine. Application of a pharmacopoeial 
light microscopy method revealed numerous glass fibres (Fig. 2D). Although passing the reconstituted solution 
through a 5 µm filter needle removed virtually all detectable glass particles, reducing the particulate burden 
within pharmacopoeial limits, such a method is unsuitable for clinical development, with the possible exception 
of very early-phase  studies31.
Initial selection of commercially-available matrices for evaluation. In our previously published 
work, we reported that the S14 matrix achieved better vaccine thermostability than an alternative commercially-
available polypropylene-based matrix  (HDC®II J200, Pall Corporation). We therefore sought to identify alterna-
tive commercially-available matrices which might offer thermostability equivalent to or better than that achieved 
with S14, but without the problem of shedding of non-biocompatible fibres. A set of seven matrices were selected 
based on manufacturers’ product specifications claiming low fibre shedding, low chemical leaching and compat-
ibility with sterilisation either by dry heat, steam or gamma-radiation sterilisation (Table 1). Henceforth matrices 
are referred to, for clarity of identification, in terms of their fibre material and the manufacturer’s product name.
We initially screened all matrices for suitable loading capacity (> 20 µL of deionised water/cm2). Matrices 
which did not absorb 20 µL/cm2 (without visible remaining beads of water within 2 s) were re-tested after treat-
ment with 2% w/v polysorbate 20 solution. Matrices which did not absorb 20 µL/cm2 after detergent treatment 
were not studied further. We proceeded to further study of the remaining five matrices along with the two previ-
ously tested matrices (glass fibre S14 and polypropylene J200).
The architecture of the selected matrices was characterised by scanning electron microscopy (Fig. 3). Fibre 
diameters estimated for each matrix type using Image J analysis are presented in Table 1.
Fibres in the polypropylene (J200) matrix (Fig. 3A) and glass fibre (conjugate pad) matrix (Fig. 3F) shared 
the straight, rod-like fibre morphology seen in the original glass fibre (S14) matrix (Fig. 2A,B) but had larger 
fibre diameters of 10–20 μm (as compared to 4 μm in the S14 glass fibre sample). The remaining four matrices 
(Fig. 3B–E) exhibited a greater degree of curl along their length. A film was apparent on the glass fibre matrix 
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Figure 2.  SMT on S14 results in thermostable vaccine embedded in sugar glass. (A) and (B) show scanning 
electron micrographs of S14, respectively before and after loading and drying of 0.5 M (80:20) trehalose:sucrose. 
In panel (A), the arrangement of fibres in S14 is apparent (× 200 magnification, 100 µm scale bar). In panel 
(B), sugar glass films are visible between fibres (main panel at × 200 magnification with 100 µm scale bar, inset 
at × 1000 magnification with 20 µm scale bar). Panel (C) shows recovery of vaccine from matrix loaded with 
a human dose of adenovirus, both immediately post-drying and after thermochallenge at 30 °C for 1 month. 
Results plotted illustrate total virus recovery from each replicate matrix (n = 4 for − 80 °C comparator, n = 2 for 
post-drying, n = 3 for post-thermochallenge), with lines indicating the mean of the replicates. Numbers above 
each result show  log10-fold loss from the − 80 °C control. Panel (D) shows a representative light microscopy 
image of fibres shed from S14 after vaccine reconstitution (scale bar 200 µm).
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Table 1.  Basic characteristics of studied matrices. Loading capacity was measured by weight measurement 
of matrices before and after full impregnation in water. Fibre diameter was measured using Image J from 
SEM micrograph images. Mean pore size are as provided in suppliers’ specification (in one case N/A denotes 
data not available). Thermostabilisation performance presented is loss of infectivity after vaccine drying 
and thermochallenge for 1 week at 45 °C. Excl. denotes matrices excluded from further analysis on basis of 
loading capacity. a Proprietary composition, but macroscopic, microscopic and FTIR spectrum appearances 
are consistent with polyester (data not shown); this matrix is henceforth referred to as polyester. b Henceforth 



















S 14 GE (Whatman) Glass fibre × ✓ 55 4.2 ± 0.3 20 0.3
J200 Pall Polypropylene ✓ ✓ 36 21.7 ± 0.4 20 1
23100 Hollingsworth- Vose Polyester ✓ ✓ 43 4.4 ± 0.4 11 1.3
33100L Hollingsworth- Vose Polyamide ✓ ✓ 36 4.8 ± 0.4 27 0.9
Cyclopore (PC) GE (Whatman) Polycarbonate ✓ × Excl. Excl. Excl. Excl.
31 ET CHR GE (Whatman) Cellulose × ✓ 40 15.4 ± 1.0 1.2 2.4
Leukosorb (Leu) Pall Polyestera × ✓ 40 3.5 ± 0.2 8 1.7
Conjugate pad 
(CP) Pall Glass  fibre
b × ✓ 30 12.3 ± 0.4 N/A 0.9
Asymmetric 
polysulfone (AS) Pall Polysulfone ✓ × Excl. Excl. Excl. Excl.
A Polypropylene J200 B Polyester 23100
C Polyamide 33100L D Cellulose 31ET CHR
E Polyester leukosorb F Glass fibre conjugate pad
Figure 3.  Physical appearance of fibres and sugar glass formed in matrices. Scanning electron microscopy 
images of six different matrices at × 1000 magnification. Within each panel, the left-hand image shows empty 
matrices and the right-hand image shows fibres after loading and drying of 0.5 M (80:20) trehalose:sucrose 
solution. Scale bar shows 20 µm in each image.
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(conjugate pad) (Fig. 3F). This resembled a binder (a glue-like substance used during the production of non-
woven matrices, to hold the fibres together and ensure mechanical strength of the product). Matrices loaded with 
0.5 M sugar solution and dried at room temperature for 24 h also showed differences in the distribution of the 
sugar glass intercalated between the fibres (Fig. 3). Distinct films of sugar glass between the fibres were visible on 
the two glass fibre matrices, but not in the polyamide (33100L), polyester (leukosorb) or polypropylene (J200) 
matrices. The sugar loaded polyester (23100) matrix and cellulose (31 ET CHR) matrices showed a glazing effect 
on the fibres, with discrete sugar glass films being apparent.Adenovirus vaccine vectors were formulated in 0.5 M 
TS and dried on the five selected matrices, with glass fibre (S14) and polypropylene (J200) matrices as compara-
tors of known performance. Dried matrices were thermochallenged for a week at 45 °C prior to reconstitution 
and infectivity titration. Marked thermostabilisation performance differences between the matrices were appar-
ent (Table 1), with none of the alternative matrices matching the performance of S14. The next-best-performing 
matrices were polyamide (33100L) and glass fibre (conjugate pad), with infectivity loss of 0.9  log10-fold in each. 
The cellulose-based matrix (GE) performed most poorly.
To understand the highly variable thermostabilisation performance of the matrices, we investigated whether 
performance could be correlated with the physical properties of the matrices or the sugar glass formed. 0.5 M 
[50:50] trehalose sucrose was loaded into each matrix and dried at room temperature and < 5% relative humid-
ity. Dried samples were then subjected to modulated differential scanning calorimetry (DSC) to measure glass 
transition temperature (Tg) onset temperature and enthalpic recovery of the sugar glass formed on the matrices. 
The glass transition temperature  (Tg) indicates the temperature at which a low mobility sugar glass changes to 
a highly mobile rubbery state and is known to be related to product stability in dry  formulations32. Enthalpic 
recovery is a measure of energy dissipated as a glass progresses through equilibrium and can reflect molecular 
rearrangement during storage or physical  ageing33.
The  Tg was similar for all matrices, observed over a narrow range between 52 and 56 °C, and did not correlate 
with thermostability (Fig. 4A). A possible correlation was observed between thermostabilisation performance 
and high enthalpic recovery (Fig. 4B,  r2 = − 0.70, p = 0.02), as seen with glass fibre matrices conjugate pad and 
S14 followed by polypropylene (J200) based matrix; to our knowledge this is not a parameter amenable to con-
trolled manipulation and we did not evaluate this further. There was substantial variation in the residual mois-
ture content of products dried under the same conditions on different matrices (Fig. 4C), the best performing 
matrix, S14 having relatively low residual moisture. Recovery of a model protein (lysozyme) after desiccation 
and reconstitution did not predict thermostabilisation performance (Fig. 4D).
Given the multiple parameters differing between the matrices, and the lack of a readily modified parameter 
correlated with performance, this line of enquiry was not pursued further.
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Figure 4.  Relationships of sugar glass properties with vaccine thermostability on various matrices. Each panel 
relates the thermostabilisation performance of the various matrices (after 1-week thermochallenge at 45 °C, 
Y-axis, data shown in Table 1) to a potentially explanatory variable on the X-axis: glass transition temperature 
(panel A); enthalpic recovery (panel B); moisture content (panel C); and protein recovery (panel D). Results of 
Pearson correlation analysis are shown within each panel. DSC measurements (panels A and B) were made in 
singlicate, Karl–Fischer measurements (panel C) were made in duplicate, and protein loss measurements (panel 
D) were made in triplicate. For panels (C) and (D), points represent the mean measurement.
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Characterisation of S14 glass fibre matrix. Given our inability to identify a commercially-available 
matrix suitable for clinical application, we turned our attention to detailed characterisation of the best-perform-
ing S14 matrix, with a view to future production of a similar matrix from biocompatible materials.
We initially performed a more extensive characterisation of the physical properties of the matrix, with results 
as shown in Table 2.
Use of chemical binders is common in the production of nonwoven fabrics such as S14 to provide strength 
and desirable surface properties. In view of the possibility that a binder might be contributing to S14’s thermo-
stabilisation performance, we investigated whether such a binder could be identified in the matrix.
Scanning electron microscopy demonstrated film-like material which could represent binder covering fibres 
in some sections of the S14 sample (Fig. 5A). Differential scanning calorimetry and thermogravimetric analysis 
(Fig. 5B,C) demonstrated the presence of a material with a melting point of 220 °C and a degradation tempera-
ture at 260 °C.
For further characterisation, the binder was extracted in liquid and freeze dried. Fourier transform infrared 
(FTIR) spectroscopy of the extract provided a fingerprint spectrum, which matched closely with the expected 
spectrum of polyvinyl alcohol (PVA) (Fig. 5D)34,35. The presence of PVA in the matrix is also supported by above 
DSC results, indicating a melting transition in the range of 180–240 °C, typical of  PVA36.
The solubility and other properties of PVA vary widely according to molecular weight (MW) and degree of 
hydrolysis, and so we sought to further characterise the presumed PVA extracted from S14. We used dynamic 
light scattering (DLS) to compare the hydrodynamic radius of the PVA extract to those of PVA samples of known 
MW. The results were consistent with a MW in the range of 35 kDa (Fig. 5E).
We then used 1H NMR to estimate the degree of hydrolysis of the polymer. The 1H NMR spectrum obtained 
(Fig. 5F) was consistent with PVA, with a 2:1 ratio of the areas under the peaks at ~ 1.6 ppm and 3.9 ppm (cor-
responding to hydrogens in the  CH2 and CH environments respectively). Results obtained using a range of 
standards of varying percentage hydrolysis showed a clear relationship of the size of a peak at 2.05 ppm to the 
acetyl group content (the presence of which, in a sample of PVA, indicates incomplete hydrolysis). The spectra 
of the completely hydrolysed standard and the S14 extract were similar, with only a trace of a peak in this area, 
and so we concluded that the PVA extracted from S14 is likely to be completely hydrolysed.
PVA enhances adenovirus stabilisation by SMT. Having identified PVA in the best-performing 
matrix, S14, we investigated whether the PVA may function not only as a binder but might actually contribute 
to vaccine thermostabilisation.
We reasoned that treatment with PVA might enhance the thermostabilisation performance of relatively 
poorly-thermostabilising matrices. We observed that application of PVA extracted from glass fibre (S14) sig-
nificantly improved thermostabilisation performance of two of the three tested matrices, as assessed by infec-
tious virus recovery after a 4 week 45 °C thermochallenge. Recovery from the polyester matrix (Leukosorb) was 
enhanced by 1.3  log10-fold, while enhancement from the cellulose matrix (ET CHR) was enhanced by 2  log10-fold 
(Fig. 6A). Addition of PVA to a glass fibre matrix (Pall’s conjugate pad) was not beneficial. This matrix already 
contains a binder (Fig. 3F), possibly PVA.
We proceeded to test whether the degree of hydrolysis of PVA had any impact on vaccine thermostability at 
45 °C for an extended period of 28 days. We tested polyester (Leukosorb), polyamide (33100L) and a custom-
made glass fibre-based matrix after treatment with PVA extracted from S14 and two other commercially sourced 
polymers (Sigma) which were similar in size but differed in degree of hydrolysis (30–70 kDa/87–90% hydro-
lysed, and 31–50 kDa/> 99% hydrolysed). We again observed substantial improvements in thermostabilisation 
performance, exceeding a 1  log10-fold increase in infectious virus recovery after thermochallenge, when PVA 
was applied to matrices which did not contain PVA at baseline (polyamide and polyester) (Fig. 6B). The greatest 
Table 2.  Physical characteristics of glass fibre (S14) and PVA matrices. ND not done. Characteristics of S14 
are relevant throughout the “Results” section. PVA matrices PVA1-6 are introduced in the final subsection 
of “Results”, and are relevant only to that subsection. The nomenclature ‘PVA1-6’ refers to six commercially 
available PVA matrices from within a range produced by Kuraray Co (Japan), as described in the text.
S14 PVA1 PVA2 PVA3 PVA4 PVA5 PVA6
Areal density (g·m−2) 55 12 24 36 48 60 84
Thickness (μm) 510 40 73 136 170 190 270
Fibre diameter (µm) 3.4 21 21 22 23 22 22
Fibre length (mm) 4.4 4.4 4.2 4.1 4.5 4.0 4.3
Largest pore diameter (µm) 133 ND ND ND ND ND ND
Mean flow pore diameter (µm) 22 ND ND ND ND ND ND
Smallest pore diameter (µm) 6 ND ND ND ND ND ND
Porosity (%) 95 75 72 78 76 73 73
Capillary constant  (cm5) 7.7 ×  10–7 ND ND ND ND ND ND
Virus-aqueous sugar solution contact angle (°) 31 ND ND ND ND ND ND
Virus-aqueous sugar solution surface tension (mN·m−1) 64 ND ND ND ND ND ND
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enhancement was seen with the S14 extract, followed by the fully hydrolysed PVA, with the least enhancement 
seen with the incompletely hydrolysed PVA (Fig. 6B).
Next, we tested whether the understanding we had gained would enable us to produce an ‘in-house’ wet-laid 
glass fibre matrix which could replicate S14’s thermostabilisation performance. The new matrix had structural 
properties similar to those of S14 (area density 50.6 ± 1.5 g·m−2, thickness 0.56 ± 0.02 mm, mean flow pores 
25 ± 2.3 µm, absorption capacity 11.1 ± 0.3 g/g, composed of borosilicate glass fibres with diameter 3.6 ± 1.8 and 
length 1.3 ± 0.6 mm; see Table 2 for data relating to S14), and a similar appearance (Fig. 6C). Although thermo-
stabilisation performance of the custom-made matrix did not exactly match that of S14 (Fig. 6D), it was closer 
than had previously been achieved with any of the other tested matrices (Table 1 and Fig. 6B). As expected, 
further modification of the matrix with additional PVA had no effect.
Matrices composed of PVA have potential to achieve good stability with reduced shed-
ding. Having established that the presence of PVA in glass fibre matrices could enhance adenovirus stability, 
we identified six commercially-available matrices composed entirely of PVA (both fibres and binder). The only 
identifiers provided by the supplier (Kuraray Co, Japan) for these matrices were the catalogue numbers BFN1-6. 
Henceforth these matrices are referred to as PVA1-6. Physical characteristics of these matrices were measured 
(Table 2). The PVA matrices had a range of thicknesses and hence areal densities, but otherwise shared similar 
structures as each other. Compared to S14, the PVA matrices had porosity somewhat lower than that of S14 (75% 
vs 95%), substantially thicker fibers than S14 (c. 22 μm vs 3.4 μm), and similar fiber length (c. 4 mm).
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Figure 5.  Chemical properties of glass fibre matrix. Panel (A) shows a scanning electron microscopy image 
indicating presence of binder in glass fibre (S14), visible as a film in the white-circled area. Scale bar shows 
10 µm. Such areas were relatively sparse, compared to the extensive films apparent in matrices imaged after 
loading and drying of trehalose:sucrose solution (Fig. 2B). Panel (B) shows a differential scanning calorimetry 
thermogram of glass fibre (S14), representative of duplicate measurements. The graphs show heat flow as a 
function of temperature during scanning from 40 to 250 °C. Panel (C) displays thermogravimetric analysis of 
glass fibre (S14), showing a thermal decomposition step. Weight losses (green lines) and the rate of weight loss 
(i.e. derivative, %/°C) (blue lines) are shown. Panel (D) shows the sample spectrum obtained from attenuated 
total reflectance Fourier transform spectroscopy (ATR-FTIR) for the binder recovered from glass fibre (S14) 
(black), and a reference library spectrum for PVA (grey). Panel (E) shows estimation of the molecular weight of 
the binder extracted from glass fibre (S14) by DLS. Points and solid line show a standard curve generated using 
PVA of known MW. Dashed lines indicate the hydrodynamic radius of the PVA extracted from S14 (11 nm) 
and the inferred MW (36 kDa). Points and error bars indicate the mean and range respectively of duplicate 
DLS measurements. Panel (F) shows 1H NMR spectra used to estimate the percentage hydrolysis of the 
binder extracted from glass fibre (S14). The upper spectrum (labelled S14) is that of the extract, with unknown 
percentage hydrolysis and hence an unknown percentage of monomers bearing acetyl groups. The five spectra 
below were obtained using standards prepared by proportionately mixing 80% and 100% hydrolysed PVA to 
achieve a range of acetyl group content ranging from < 0.1% up to 20% (as per labels to left of panel). The X-axis 
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Matrices were then screened for loading capacity. PVA2-6 had loading capacity > 50 μL/cm2; a visible bead 
of fluid remained on PVA1 at 50 μL/cm2 and it was therefore excluded from further investigation. We then 
imaged matrices after drying of mock samples. Matrices were subjected to SEM after drying of 50 μL/cm2 0.5 M 
trehalose:sucrose (50:50) (Fig. 7A,B), and to confocal laser scanning microscopy after drying of a similar sample 
with added 10 mg/mL fluorescein-labelled lysozyme as a model proteinaceous load (Nanocs Inc, USA) (Fig. 7C). 
As compared to S14, it was apparent that drying on PVA matrices resulted in more widespread formation of 
sugar film around and between the fibres. We next assessed the mechanical robustness of the PVA matrices: upon 
reconstitution of a dried sugar solution, there was little evidence of fibre shedding (Fig. 7D).
Finally, we tested the performance of the PVA matrices in stabilisation of adenovirus. When assessed by ther-
mal challenge at 30 °C or 45 °C for 1 month, vaccine stabilisation on PVA2-6 was consistently favourably compa-
rable to that on S14 (Fig. 7E). We did however observe substantial variation between the duplicate experiments 
in stability at 30 °C, and stability at 45 °C on all matrices (including S14) was inferior to that seen previously.
Discussion
The starting point for the present study was the observation, in our previous work, that the non-biocompatible 
glass-based S14 matrix out-performed a polypropylene  matrix28. This posed the question of which properties 
of the matrix could be relevant for SMT performance, and whether a more suitable matrix than S14 could be 
identified for clinical translation.
Our initial attempts to find a suitable commercially available matrix yielded disappointing results. Adeno-
virus stability on the tested matrices was poor (Table 1). Multiple variables differed between each matrix, and 
we were therefore unable to perform experiments to clearly isolate the effect of a single variable. There was not 
a clear relationship between characteristics of the matrices and their stabilisation performance (Figs. 3 and 4), 
with the possible exception of high enthalpic recovery of sugar glass (which is not a parameter which can readily 
be ‘designed in’ to a new matrix).
Our ability to use analysis of commercially available matrices to draw conclusions to guide design of new 
biocompatible matrices was thus limited. We therefore changed our strategy, seeking to characterise S14 in detail 
and produce similar matrices ‘in-house’, allowing us to identify features of S14 contributing to its stabilising 
performance.
Most significantly we found that PVA, present on the S14 matrix as a binder, appears to contribute to the 
stability of adenovirus (Figs. 5 and 6). It was shown that fully hydrolysed PVA, similar to that we extracted from 
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Figure 6.  PVA improves vaccine thermostability on matrices. A PVA-containing extract prepared from S14 
was dried onto various fresh matrices, followed by drying of vaccine in 0.5 M (50:50) trehalose-sucrose onto the 
treated matrices and untreated comparator matrices. Viable virus recovery was assessed after thermochallenge 
as indicated for each panel. S14 was included as a comparator in each experiment. Panel (A) shows loss in 
infectivity titre of vaccine in the absence (open circles) or presence (solid circles) of PVA extracted from glass 
fibre (S14), as compared to − 80 °C stored liquid control, after 1 week at 45 °C. Points indicate individual 
samples (four replicates per condition). Panel (B) shows difference in loss in infectivity titre of vaccine loaded 
in polyester (leukosorb) and polyamide (33100L) matrix modified by deposition of three different types of PVA 
prior to application and drying of vaccine. Dried samples were subjected to thermochallenge for 4 weeks at 
45 °C. Points indicate individual samples (three replicates per condition). Panel (C) shows a scanning electron 
microscope image of the custom-made glass fibre matrix. Scale bar shows 50 µm. Panel (D) compares loss in 
infectivity titre of vaccine post-thermochallenge between standard 14 and custom-made glass fibre matrix 
modified by deposition of two different types of PVA prior to application and drying of vaccine. Dried samples 
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S14, was most beneficial in thermostabilisation (Fig. 6). Polyvinyl alcohol is potentially suitable for use as an 
excipient in vaccine formulations: it is ‘generally regarded as safe’ (GRAS) and is also a FDA approved inactive 
ingredient for parenteral  use37. PVA has previously been explored as an excipient in a number of studies of bio-
macromolecular stability. It has been found to be beneficial in some formulations of proteins, including  insulin38, 
but benefit has not been seen consistently in other  studies39–41. PVA may contribute to protein stability by hydro-
gen bonding of hydroxyl groups in PVA to the proteins. In dried protein formulations, PVA has also been shown 
to prevent deamidation more potently than another widely used polymeric excipient, polyvinyl  pyrrolidone42.
We were subsequently able to demonstrate that matrices composed entirely of PVA could achieve stability 
performance favourably comparable to S14. PVA is biocompatible and these matrices shed few fibres during 
sample reconstitution. These matrices therefore appear more suitable for clinical application than our previous 
gold-standard glass-fibre matrix.
This work was performed as part of an effort to develop the SMT technology for Good Manufacturing Prac-
tice (GMP) compliant manufacture of a product suitable for an early-phase clinical trial. This work faced two 
principal challenges: identification of a suitable matrix, and identification of means of performing the process 
reliably under GMP-compliant conditions. We believe PVA matrices offer a potential solution to the former, but 
we have not yet been able to achieve sufficient process reliability to support clinical translation.
Figure 7E shows an example of process variability between replicate experiments, and overall poor perfor-
mance in terms of stability at 45 °C. These experiments were performed by drying in a lyophilizer (with atmos-
pheric pressure and room temperature, i.e. using the lyophilizer only to provide a low humidity temperature-
controlled environment). We have however observed similar process variability across numerous additional 
experiments drying within a glovebox (as used for experiments 1–5) or dessicator. Extensive efforts to find 
















































































































Experiment B, 45 °C
Figure 7.  Characterisation of PVA matrices. Panels (A)–(D) compare S14 (upper row of images) and PVA6 
(lower row). Images with matrices PVA2-5 were similar to those shown for PVA6. Panels (A)–(C) show the 
distribution of sugar-glass film after drying of 0.5 M (50:50) trehalose:sucrose solution (50 μL/cm2): (A) shows 
SEM at low magnification (scale bar = 500 μm); (B) shows SEM at higher magnification (scale bar = 50 μm); (C) 
shows confocal laser scanning microscopy of the distribution of fluorescein-labelled lysozyme within the film 
(scale bar = 50 μm). (D) Show results of light microscopy for subvisible particle detection after reconstitution of 
dried 0.5 M (50:50) trehalose:sucrose solution (scale bar = 1 mm). (E) compares loss in infectivity titre of vaccine 
post-thermochallenge between PVA-based matrices (PVA2-6) and S14 glass fibre matrix. As indicated in the 
graph headings, dried samples were subjected to thermochallenge for 4 weeks at 30 or 45 °C, and the experiment 
was performed in duplicate. Points indicate individual samples (three replicates per condition).
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optimal conditions (investigating the effects of changing temperature and duration of drying, as well as excipient 
composition) have been unsuccessful in resolving the variability.
We hope that future work may resolve these remaining challenges. If consistency of performance could be 
achieved, SMT offers ability to stabilise adenovirus for months at 45 °C which is, to our knowledge, unmatched 
by other stabilising approaches. The current study, however, highlights the potentially beneficial effect of PVA 
upon adenovirus stability. This may be of relevance not only for the SMT approach, but potentially for other 
approaches to stabilising vaccines based upon this important platform.
Methods
Viruses and infectivity titration. Simian adeno virus vectors ChAd63-METRAP and ChAdOx2-RabGP 
were prepared, purified and tested for quality by the Jenner Institute Viral Vector Core Facility, as previously 
 described30,43. Viruses were dialysed against either a previously used storage buffer (10  mM Tris, 7.5% w/v 
sucrose, pH 7.8) or unbuffered 0.5 M (50:50) trehalose and sucrose and stored at − 80 °C as stock. ChAdOx1 
expressing Photinus pyralis  luciferase44 was prepared as previously described, with tangential flow filtration into 
unbuffered 0.5 M (50:50) trehalose and  sucrose45. Typical preparations were supplied and stored at a titre of c. 
1 ×  1012 virus particles (VP) per mL, corresponding to c. 1 ×  1010 infectious units (IU) per mL and hence a par-
ticle: infectivity ratio of c. 100.
For infectivity titration of ChAd63-METRAP and ChAdOx2-RabG, duplicate fivefold serial dilutions were 
prepared in complete DMEM (10% FCS, 100 U penicillin, 0.1 mg streptomycin/mL, 4 mM l-glutamine) and 
used to infect 80–100% confluent HEK293-TRex cells (ThermoFisher) grown in 96-well plates (BD Purecoat 
Amine, BD Biosciences, Europe). Infected cells were immunostained and imaged as previously  described46. Wells 
containing 20–200 spots were used to back-calculate recovered infectious units.
Infectivity titration of ChAdOx1 luciferase was performed as above with the exception that, 24 h after infec-
tion, cells were lysed by addition of 1% Triton X-100 (Sigma) and luciferase activity measured using a Bright-Glo 
assay kit (Promega). Infectivity was calculated by interpolation on a standard curve prepared by serial dilution 
of a sample of known infectivity.
Drying, thermochallenge and reconstitution. Stock vaccines were thawed and diluted into unbuff-
ered 0.5 M trehalose–sucrose solution. Dilution factors, final viral titres, and the trehalose:sucrose ratio varied 
between experiments, as stated in figure legends.
For data other than Fig. 7E, fibrous matrix was cut into 100  mm2 pieces, loaded with vaccine or sugar solu-
tions (as described in individual figure legends) and transferred to a glove box (Coy Laboratory Products). An 
activated silica bed within the chamber and circulation of air through desiccation capsules containing anhydrous 
calcium sulphate (Drierite™, W.A. Hammond Drierite Co.), regulated by a humidity controller (Series 5000, 
Electro-tech Systems), was used to maintain relative humidity beneath 5%. A portable datalogger (AET-175, 
ATP instruments) was used for recording changes in relative humidity and temperature during the desiccation 
process. The temperature inside the enclosed glove box remained between 22 and 25 °C for all experiments.
For data shown in Fig. 7E, drying was performed similarly except for use of a lyophilizer rather than glove-
box to provide a room temperature, atmospheric pressure low humidity environment: humidity was lowered by 
setting the condenser to − 70 °C, while the sample temperature was controlled by setting the shelf temperature 
to 20 °C.
Samples were transferred into 2 mL glass vials, stoppered and crimp sealed under dry conditions within the 
glove box prior to further use. Samples undergoing thermochallenge i.e. storage at elevated temperature (typically 
45 °C for 1 or 4 weeks) were stored within secondary packaging (moisture barrier bags).
For experiments involving reconstitution of dried samples, this was performed by addition of phosphate 
buffered saline (Sigma), followed by brief vortexing of the vial (1 ± 0.5 s, three times). Virus infectivity after 
reconstitution was assayed as described above. Recovery of infectious virus was quantified by comparison to a 
control sample of the starting material, included on the same assay plate. Between the set-up of an experiment 
and the assay of recovered infectivity, control samples were stored at − 80 °C in aqueous buffer (under which 
conditions loss of infectivity is known to be negligible).
Recovery was calculated in terms of  log10-fold loss in the total infectious virus content of the matrix i.e. 
 log10-fold loss =  log10(infectious units dried on matrix based on − 80 stored sample) −  log10(infectious units recov-
ered from matrix). 0.3  log10-fold loss thus implies c. 50% recovery, 0.5  log10-fold loss implies c. 30% recovery, 
and 1 log10-fold loss implies 10% recovery.
Karl Fischer moisture analysis. Residual moisture content in single matrix post-desiccation was deter-
mined with a Karl Fischer moisture analyser equipped with coulometer (Metrohm), and Hydranal-Coulomat 
titration solution (Honeywell, Fluka) in accordance with the manufacturers’ recommendations. A standard was 
used to calibrate the instrument performance (lactose standard 5%, MerckMillipore). Residual moisture content 
was expressed as a percentage (calculated from the measured mass of water as a proportion of the calculated 
mass of solutes in the loaded sample).
Measurement of subvisible particles. To produce the data shown in Fig. 2D, 100  mm2 pieces of glass 
fibre (GE Whatman Standard 14 [henceforth S14]) were cut, autoclaved at (121 °C, 15 min) and loaded with 
50 µL of sugar solution prior to drying in the glove box, vialling and reconstitution as described above. Recon-
stituted solution from 10 vials was aspirated using a syringe with a conventional 20G needle (BD Biosciences), 
to produce a single pooled unfiltered sample. Reconstituted solution from a further 10 vials was aspirated using 
a 5-μm filter needle (BD Biosciences), to produce a single pooled filtered sample. Both pools were diluted to a 
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final volume of 25 mL and tested for sub-visible particles by light microscopy according to Ph.Eur (2.9.19)/USP 
〈788〉 by a commercial testing laboratory (Reading Scientific Services Limited).
The data shown in Fig. 7D was collected using a similar but non-pharmacopoieal in-house approach, in 
which unfiltered solution from reconstitution of samples dried on S14 and PVA matrices was subjected to light 
microscopy (Leica M205C).
Scanning electron microscopy. To produce the images shown in Figs. 2, 3, 4, 5, 6, untreated matrices 
(i.e. without sputter coating) were loaded onto aluminium mounts using carbon conductive tabs and imaged 
using a Zeiss-Evo LS15 variable pressure scanning electron microscope (SEM) equipped with variable pressure 
secondary electron detector (Carl Zeiss Ltd). Imaging was performed at a chamber pressure of 50 Pa air and 
accelerating voltage of 15 kV.
To produce the images shown in Fig. 7A,B, samples were sputter coated with gold with the coating thickness 
of 30 nm using a Quorum Q150RS coating unit. They were then imaged using a Jeol JSM-6610LV scanning 
electron microscope with 5 kV accelerating voltage and beam spot size at setting 40.
Further analyses of images such as measurement of fibre diameter were made using Image J software (freely 
available, National Institutes of Health). At least 40 measurements per matrix were performed, using images 
taken at varying magnification.
Confocal laser scanning microscopy. 10 mg/mL Fluorescein-labelled lysozyme (Nanocs Inc, USA) was 
spiked into the 0.5 M trehalose:sucrose (50:50) solution and dried as above before examination by fluorescence 
confocal microscopy (DMI6000 B, Leica Microsystems, Germany).
Differential scanning calorimetry. The glass transition temperature  (Tg) of sugar glass in matrices was 
measured immediately after drying had completed using Differential Scanning Calorimetry (DSC). The melt-
ing point of the binder in untreated glass fibre (S14) was measured using DSC (Q2000, TA instruments). The 
instrument was purged with dry nitrogen (50 mg/mL) continuously during sample measurement. Calibration 
was performed prior to measurements using a certified reference material (Indium) for temperature and heat 
flow accuracy.
Multiple 6-mm diameter discs were cut out of a matrix dried with 0.5 M trehalose:sucrose (50:50). Discs 
were weighed and, for each matrix type in turn, a total mass of 5–15 mg was loaded into Aluminium DSC pans 
(TA Instruments) and hermetically sealed. Samples were subjected to a temperature ramp from − 20 to 180 °C 
at a heating rate of 10 °C per minute. Measurements on all samples were performed in duplicates. Thermograms 
relating heat flow (W/g) to temperature (°C) were analysed using Trios software (TA Instruments) for identifica-
tion of the glass transition (Tg) onset temperature.
For the measurement of enthalpic recovery, which manifests as an endothermic peak at the glass transition, 
modulated DSC (temperature modulation ± 0.50 °C every 60 s and ramp rate 3 °C/min from − 20 to 100 °C) was 
employed. The enthalpic recovery was estimated by linear peak integration in the thermograms plotted between 
nonreverse heat flow (W/g) and temperature (°C) using Universal Analysis software (TA Instruments).
Protein recovery. A 10 mg/mL solution of lysozyme (Sigma-Aldrich) was made in 0.5 M trehalose sucrose. 
25 µL was loaded into each matrix in triplicates. Protein was reconstituted from the matrices after desiccation 
overnight and recovery was quantified using EnzChek Lysozyme Assay Kit (ThermoFisher Scientific). Fluores-
cence measurements were performed in triplicates for each sample and protein recovery calculated by interpola-
tion on a standard curve, using GraphPad Prism.
Protein loss was then calculated similarly to infectivity loss (above), i.e.  log10-fold loss =  log10(micrograms of 
protein dried on matrix) −  log10(micrograms of protein recovered from matrix).
Thermogravimetric analysis. Degradation temperatures of matrix constituents were measured by ther-
mogravimetric analysis using a TGA Q500 (TA instruments). Samples loaded into a tared platinum pan just 
prior to measurement were subjected to a temperature ramp at 5 °C per minute from ambient to 550 °C in a flow-
ing nitrogen atmosphere (100 mL/min). The gas was switched to air at 550 °C (100 mL/min) and heat was con-
tinued at the rate of 5 °C/min to 730 °C. Data was analysed using Universal Analysis software (TA Instruments).
Polyvinyl alcohol (PVA) extraction and Fourier transform infrared spectroscopy. A 
500 mm × 27 mm piece of glass fibre (S14) was dissolved in 100 mL of ultrapure water by stirring and heating at 
90 °C for 48 h. The suspension was filtered through a 0.2 µm filter and the filtrate was freeze dried (Virtis AdVan-
tage 2.0, SP Scientific) to a white amorphous material. This residue was subjected to single reflection attenuated 
total reflection (MIRAacle™, Pike Technologies) Fourier transform infrared spectroscopy ATR-FTIR (Tensor 37, 
Bruker) equipped with nitrogen-cooled mercury cadmium telluride detector.
To obtain a spectrum of the sample, an average of 64 interferograms was collected at a resolution of 4  cm−1 
in the wavelength range from 4000 to 750  cm−1 and blank subtracted.
Spectra were analysed using OPUS 6.5 software (Bruker) and compared with RMIT University’s spectral 
library of organic compounds generated using Spectrum 10 software (Perkin Elmer). Fingerprint spectra shown 
in Fig. 5D were prepared using Prism 7.0 (GraphPad Software LLC).
Dynamic light scattering (DLS). The molecular weight of the PVA binder present on the glass fibre 
matrix (S14) was estimated by DLS. PVA was extracted and freeze-dried as described above. Solutions of this 
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extracted sample and standards of known polymer size were prepared in water to the concentration of approxi-
mately 1.3 mg/mL and passed through 0.22 µm and 300 kDa molecular weight cut-off filters. The sample was 
then concentrated approximately five-fold from 4 mL to 0.75 mL using a 3 kDa MWCO filter (Vivaspin, GE). 
Zetasizer Nano ZS and DTS software (Malvern Instruments) was used for measurement of hydrodynamic diam-
eter based on size distribution by volume. Independent duplicate preparations of all standards and samples were 
tested. Prism 7.0 (GraphPad Software LLC) was used to generate a standard curve plotted between measured 
hydrodynamic diameter and known average molecular weight (kDa) to interpolate size of the PVA in the extract.
Nuclear magnetic resonance (NMR) spectroscopy. The degree of hydrolysis of the PVA binder pre-
sent on the glass fibre matrix (S14) was estimated by 1H NMR measurement as the intensity of the peak attribut-
able to the acetyl group present in non-hydrolysed PVA. A 5 mg/mL aqueous solution of PVA extracted from 
the glass fibre sample (S14) was prepared in deuterium oxide. Reference spectra for PVA with varying degrees of 
hydrolysis were obtained by mixing > 99% hydrolysed PVA and 80% hydrolysed PVA in appropriate proportions 
to produce standards containing c. 0%, 2%, 5%, 10% and 20% acetyl groups, again at 5 mg/mL in deuterium 
oxide. An AVIII 700 instrument (Bruker Biospin) was used to generate 1H 1D spectra (employing a quantitative 
1D NOESY (Nuclear Overhauser Effect Spectroscopy) presaturation sequence with recovery delay  d1 = 30 s).
Application of PVA to matrices. Aqueous solutions of each type of PVA to be investigated were prepared 
at 10 mg/mL. Matrices were cut into approximately 100  mm2 pieces and loaded with until the matrices were 
saturated by the solution and air-dried overnight. The polyamide matrix (33100L) required surface modification 
by washing in 100% ethanol for 20 min and air drying before PVA could be loaded. Following PVA application, 
vaccines were dried on the matrices and thermostability assessed as described above.
Study of physical characteristics of matrices. The physical characteristics of matrices were studied 
using NWSPs (Nonwoven Standard Procedures) prescribed by the EDANA, the international trade association 
for the nonwoven industry.
Areal density was measured as ratio of mass in grams and area in square metres according to EDANA NWSP 
130.1R0 (15).
Matrix thickness was measured at an applied pressure of 0.5 kPa according to EDANA NWSP 120.1.R0 (15) 
using a thickness tester (ProGage, Thwing-Albert Instrument Company).
Fibre length was measured based on 60 individual fibres extracted from the matrix using a Leica MD G41 
optical microscope in transmission mode and Image J software.
Minimum mean and maximum pore size were obtained using a POROLUX 100 Automated Capillary Flow 
Porometer using Galpore liquid of surface tension 15.6 mN∙m-1. A total of five measurements were taken per 
sample. Porosity (ɛ) was determined by the equation ɛ = (1 − ∅) × 100% where ∅ is the volume fraction measured 
as a ratio of bulk matrix density to bulk fibre density.
The surface tension of aqueous sugar solution on the matrix was measured on a Kruss K100 tensiometer 
using the Wilhelmy plate method in which the force exerted on a suspended plate when it touches the surface 
of a liquid is related to the surface tension and the contact angle according to the equation σ = F
L·cos θ
 where 
σ = surface tension of the liquid, F = measured force, L = wetted length, and Θ = contact angle.
Wettability was evaluated using the Washburn method, again on a Kruss K100 tensiometer. The rate of mass 
uptake when the porous substrate (matrix) comes in to contact with a liquid was used to determine the capil-






 , where m = mass, t = flow time, 
c = capillary constant of the nonwoven, ρ = density of the liquid, σ = surface tension of the liquid, Θ = contact 
angle, η = viscosity of the liquid. The capillary constant of the matrix was determined using n-hexane which has 
a contact angle of 0°.
In-house production of glass-fibre-based matrix. A glass fibre matrix (Fig. 6C) was custom made 
by a wet-lay process using commercially available glass fibre and polyvinyl alcohol aiming for similar porosity, 
thickness, areal density and wetting behaviour as the glass fibre sample (S14).
Wet-lay processes are similar to paper manufacturing. Glass fibre with geometry similar to the fibres used 
in S14 was obtained (Johns Manville, type 475, diameter 4 µm). A slurry (suspension of fibres in water) was 
produced and agitated in a rig connected to water supply and drainage. Upon opening of the rig’s drainage 
outlet, the fibres were captured and retained on a fine metal mesh at the outlet, forming a nonwoven web. The 
fibrous mesh was blot dried, roller pressed and further dried at 110 °C for 15 min. 1 g/L PVA solution (> 99% 
hydrolysed, Mw 146,000–186,000 kDa, Sigma) was then applied to each side using a spray gun before drying at 
110 °C for a further 15 min.
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